Issue of Equity and Directors' Dealings

1 August 2013

Ultrasis plc

("Ultrasis" or the "Company")

Issue of Shares under Share Incentive

Ultrasis, the provider of interactive health care services, announces the issue of 11,352,264 new ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") under its Share Incentive Plan ("SIP"), which was previously announced on 18 October 2011.

As participants in the SIP and Directors of the Company, John Smith (Chief Executive) and Charlie Martin (Executive Director) have, as required by the AIM Rules, notified the Company that they acquired the following Ordinary Shares ("Partnership Shares") and have been conditionally awarded the following Ordinary Shares ("Matching Shares"), under the terms of the SIP and at a price of 0.22p each (being the lower of the price at the start of the accumulation period and the price on the acquisition date as set out in the HMRC approved SIP rules):

The SIP is open to all employees on the same terms where, for every Ordinary Share purchased by an employee, the Company will match it with two Matching Shares. The Matching Shares are released at the end of a three year holding period (subject to the SIP rules) and the maximum amount that may be invested in Partnership Shares in any tax year is £1,500 per employee. John Smith and Charlie Martin have each committed to invest the maximum of £125 per month.

Following this transaction, John Smith and Charlie Martin now hold the following Ordinary Shares, together with options over the same (including Matching Shares) and exercisable at various prices up to 1.35 pence, as follows:

Application has been made for the 11,352,264 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is anticipated to occur on 8 August 2013.

For the purposes of the Financial Services Authority's Disclosure and Transparency Rules, the total number of Ordinary Shares in issue following Admission will be 1,719,990,469 each carrying the right to one vote.

The above figure of 1,719,990,469 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Ultrasis under the FSA's Disclosure and Transparency Rules.

For further information contact:

 Chris Lawrance